Home » Stock Quotes » STO:AZN

AstraZeneca plc STO:AZN

Today's live share price, quote history, chart & news

870.10 SEK
-29.50 (-3.28%)
Price open 907.20
Previous close 899.60
Market cap 1.13T
Volume 1M
Day high 907.30
Day low 858.40
Year high 984.90
Year low 700.00

About AstraZeneca plc

AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Lumoxiti, Enhertu, Faslodex, Zoladex, Iressa, Arimidex, Casodex/Cosudex, and other products for oncology diseases; and Brilinta/Brilique, Farxiga/Forxiga, Bydureon, Onglyza, Byetta, Symlin, Qtern, Lokelma, Crestor, Seloken/Toprol-XL, Atacand1/Atacand HCT/Atacand Plus, Kombiglyze XR, Komboglyze, Xigduo/Xigduo XR, and other products for cardiovascular, renal, and metabolism diseases. The company's marketed products also comprise Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi Aerosphere, Breztri Aerosphere, and other products for respiratory diseases; Synagis and Fluenz Tetra/FluMist Quadrivalen for infections; Seroquel IR/Seroquel XR, Movantik/Moventi and Vimovo for neuroscience diseases; Nexium and Losec/Prilosec for gastroenterology diseases. It serves primary care and specialty care physicians through distributors and local representative offices. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.

Name AstraZeneca plc
Exchange Stockholm Stock Exchange
Sector Healthcare
Industry Drug Manufacturers—General
Country United Kingdom
Full time employees 70,600

Investing is speculative. When investing your capital is at risk. This site is not intended for use in jurisdictions in which the trading or investments described are prohibited and should only be used by such persons and in such ways as are legally permitted. Your investment may not qualify for investor protection in your country or state of residence, so please conduct your own due diligence. This website is free for you to use but we may receive commission from the companies we feature on this site. Click here for more information.